Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Phase 2CompletedNCT00863538

Kissei Pharmaceutical Co., Ltd.40 enrolled

Overview

To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Spinocerebellar Degeneration

Interventions

KPS-0373DRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * SCD with mild to moderate ataxia Exclusion Criteria: * Patients with secondary ataxia * Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Locations (3)

Japan

Hokkaido Region, Japan

Japan

Kansai Region, Japan

Japan

Kanto Region, Japan

Outcomes

Primary Outcomes

Scale for the assessment and rating of ataxia (SARA), ADL(Flow-FIM), Patient Improvement Impression

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.